Cargando…
Cardiovascular effects of fingolimod: A review article
Multiple sclerosis (MS) is a chronic auto-immune disease. Most therapeutic strategies for treatment of this disease direct immune modulation and control of inflammatory processes. First-line therapeutic agents showed moderate efficacy and frequent side-effects with moderate efficacy in trials. Their...
Autores principales: | Behjati, Mohaddeseh, Etemadifar, Masoud, Abdar Esfahani, Morteza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Neurological Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240927/ https://www.ncbi.nlm.nih.gov/pubmed/25422729 |
Ejemplares similares
-
The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
por: Abdar, Morteza, et al.
Publicado: (2016) -
Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015) -
The concept of Maslow's pyramid for cardiovascular health and its impact on “change cycle”
por: Behjati, Mohaddeseh
Publicado: (2014) -
Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model
por: Najarzadegan, Niloofar, et al.
Publicado: (2022) -
Suggested indications of clinical practice guideline for stem cell-therapy in cardiovascular diseases: A stepwise appropriate use criteria for regeneration therapy
por: Behjati, Mohaddeseh
Publicado: (2013)